Animal modeling and neurocircuitry of dual diagnosis

Journal of Dual Diagnosis

Volumn 3, Issue 2, 2007, Pages 19-29

  Chambers, R Andrew ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction; Animal models; Dopamine; Dual diagnosis; Glutamate; Hippocampus; Mental illness; Nucleus accumbens; Schizophrenia

Indexed keywords

CORTICOSTEROID; DOPAMINE;

ADDICTION; AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; BRAIN CORTEX; BRAIN INJURY; BRAIN STEM; COCAINE DEPENDENCE; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; HIPPOCAMPUS; HISTOPATHOLOGY; LONG TERM POTENTIATION; MENTAL DISEASE; MENTAL STRESS; MESENCEPHALON; NEUROIMAGING; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; SCHIZOPHRENIA; VENTRAL TEGMENTUM;

EID: 34250769617     PISSN: 15504263     EISSN: 15504271     Source Type: Journal    
DOI: 10.1300/J374v03n02_04     Document Type: Conference Paper

References (60)

1. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry. 1986;143:993-7.
2. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL et al. Comorbidity of mental disorders with alcohol and other drugs of abuse. JAMA. 1990;264(19):2511-8.
3. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S et al. Lifetime and 12-month prevalence of DSM-IIIR psychiatric disorders in the United States. Results from the NCS. Arch Gen Psychiatry. 1994;51:8-19.
4. Trull TJ, Sher KJ, Minks-Brown C, Durbin J, Burr R. Borderline personality disorder and substance use disorders: A review and integration. Clin Psychology Rev. 2000;20(2):235-53.
5. Bucholz KK. Nosology and epidemiology of addictive disorders and their comorbidity. Addictive Disorders. 1999;22(2):221-39.
6. Ling W, Compton P, Rawson R, Wesson DR. Neuropsychiatry of alcohol and drug abuse. In: Fogel B, Schiffer R, Rao S, editors. Neuropsychiatry. Baltimore, MD: Williams and Wilkins; 1996. pp. 679-721.
7. Self DW, Nestler EJ. Molecular mechanisms of drug reinforcement and addiction. Ann Rev Neurosci. 1995;18:463-95.
8. Bozarth MA, Wise RA. Involvement of the ventral tegmental dopamine system in opoid and psychomotor stimulant reinforcement. In: Harris L, editor. NIDA research monograph. Washington, DC: NIDA. 1986; pp. 190-6.
9. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. PNAS, USA. 1988;85:5274-8.
10. Nestler E, Barrot M, Self D. ?FosB: A sustained molecular switch for addiction. PNAS, USA. 2001;98(20):11042-6.
11. Thomas MJ, Beurrier C, Bonci A, Malenka RC. Long-term depression in the nucleus accumbens: A neural correlate of behavioral sensitization to cocaine. Nature Neurosci. 2001;4(12):1217-23.
12. Robinson TE, Gorny G, Mitton E, Kolb B. Cocaine self-administration alters the morphology of dendrites and dendritic spines in the nucleus accumbens and neocortex. Synapse. 2001;39:257-66.
13. Brady KT, Sinha R. Co-occurring mental and substance use disorders: The neurobiological effects of chronic stress. Am J Psychiatry. 2005;162:1483-93.
14. Chambers RA, Krystal JK, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry. 2001;50:71-83.
15. Cuffel BJ. Comorbid substance use disorder: Prevalence, patterns of use, and course. New Directions in Mental Health Services. 1996;70:93-105.
16. Weinberger DR, Lipska BK. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: A search for common ground. Schiz Res. 1995;16:87-110.
17. Weinberger DR, Aloa MS, Goldberg TE, Berman KF. The frontal lobes and schizophrenia. J Neuropsychiatry. 1994;6:419-27.
18. Bogarts B, Lieberman JA, Ashtari M, Bilder RM, Degreef G, Lerner G et al. Hippocampus-amygdala volumes and psychopathology in schizophrenia. Biol Psychiatry. 1993;33:236-46.
19. Arnold SE, Franz BR, Gur RC, Gur RE, Shapiro RM, Moberg PJ et al. Smaller neuron size in hippocampal subfieldws that mediate cortical-hippocampal interactions. Am J Psychiatry. 1995;152(5):738-48.
20. Crow TJ, Deakin JFW, Longden A. The nucleus accumbens-possible site of action of antipsychotic action of neuroleptic drugs? Physiol Medicine. 1977;7:213-21.
21. Pennartz CMA, Groenewegen HJ, Lopez da Silva FH. The nucleus accumbens as a complex of functionally distinct neuronal ensembles: An integration of behavioral, electrophysiological and anatomical data. Prog Neurobiology. 1994;42:719-61.
22. Swanson LW. Cerebral hemisphere regulation of motivated behavior. Brain Res. 2000;886:113-64.
23. O' Donnell P, Greene J, Pabello N, Lewis BL, Grace AA. Modulation of cell firing in the nucleus accumbens. Ann NY Acad Sci. 1999;877:157-75.
24. Everitt BJ, Wolf ME. Psychomotor stimulant addiction: A neural systems perspective. J Neurosci. 2002;22(9):3312-20.
25. Finch DM. Neurophysiology of converging synaptic inputs from the rat prefrontal cortex, amygdala, midline thalamus, and hippocampal formation onto single neurons of the caudat/putamen and nucleus accumbens. Hippocampus. 1996;6:495-512.
26. Mulder AB, Arts MPM, Lopes da Silva FH. Short- and long-term plasticity of the hippocampus to nucleus accumbens and prefrontal cortex pathways in the rat, in vivo. Eur J Neurosci. 1997;9:1603-11.
27. Wolf ME, Dahlin SL, Hu XT, Xue CJ, White K. Effects of lesions of prefrontal cortex, amygdala, or fornix on behavioral sensitization to amphetamine: Comparison with N-methyl-D-aspartate antagonists. Neuroscience. 1995;69(2):417-39.
28. Schmelzeis MC, Mittleman G. The hippocampus and reward: Effects of hippocampal lesions on progressive-ratio responding. Behav Neurosci. 1996;110(5):1049-66.
29. Weissenborn R, Robbins TW, Everitt BJ. Effects of medial prefrontal or anterior cingulate cortex lesions on responding for cocaine under fixed-ratio and second-order schedules of reinforcement in rats. Psychopharmacology. 1997;134:242-57.
30. Evenden JL. Varieties of impulsivity. Psychopharmacology. 1999;146(4): 348-61.
31. Moeller FG, Barratt ES, Dougherty DM, Schmitz JM, Swann AC. Psychiatric aspects of impulsivity. Am J Psychiatry. 2001;158(11):1783-93.
32. Bechara A. Risky Buisness: Emotion, decision-making and addiction. J Gambling Stud. 2003;19(1):23-51.
33. Bremner JD, Randall P, Scott TM, Bronen RA, Seibyl JP, Southwick SM et al. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry. 1995;152(7):973-81.
34. Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal volume reduction in major depression. Am J Psychiatry. 2000;157(1): 115-8.
35. Driessen M, Herrmann J, Stahl K, Zwaan M, Meier S, Hill A et al. Magnetic resonance imaging of the hippocampus and the amygdala in women with borderline personality disorder and early traumatization. Arch Gen Psychiatry. 2000;57(12): 1115-22.
36. Blumberg HP, Kaufman J, Martin A, Whiteman R, Zhang JH, Gore J et al. Amygdala and hippocampal volumes in adolescents and adults with bipolar disorder. Arch Gen Psychaitry. 2003;60:1201-8.
37. Lipska BK, Jaskiw GE, Weinberger DR. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: A potential animal model of schizophrenia. Neuropsychopharmacology. 1993;9(1):67-75.
38. Scheibel AB, Conrad AS. Hippocampal dysgenesis and schizophrenic man: Is there a relationsip? Schizophrenia Bull. 1993;19(1):21-33.
39. Lipska BK, Weinberger DR. Subchronic treatment with haloperidol and clozapone in rats with neonatal excitotoxic hippocampal damage. Neuropsychopharmacology. 1994;10(3):199-205.
40. Lipska BK, Swerdlo NR, Geyer MA, Jaskiw GE, Braff DL, Weinberger DR. Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology. 1995;122:35-43.
41. Chambers RA, Moore J, McEvoy JP, Levin ED. Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. Neuropsychopharmaclogy. 1996;15(6):587-94.
42. Grecksch G, Bernstein HG, Becker A, Hollt V, Bogerts B. Disruption of latent inhibition in rats with posttnatal hippocmapal lesions. Neuropsychopharmacology. 1999;20(6):525-32.
43. Becker A, Grecksch G, Bernstein HG, Hollt V, Bogerts B. Social behavior in rats lesioned with ibotenic acid in the hippocampus: Quantitative and qualitative analysis. Psychopharmacology. 1999;144(4):333-8.
44. Becker A, Grecksch G. Social memory is impaired in neonatally ibotenic acid lesioned rats. Behav Brain Res. 2000;109(1):137-40.
45. Sams-Dodd F, Lipska BK, Weinberger DR. Neonatal lesions of the rat ventral hippocampus results in hyerlocomotion and defecits in social behavior in adulthood. Psychopharmacology. 1997;132(3):303-10.
46. Bernstein HG, Grecksch G, Becker A, Hollt V, Bogerts B. Cellular changes in rats brain areas associated with neonatal hippocampal damage. Neuroreport. 1999;10(11):2307-11.
47. Lillrank SM, Lipska BK, Bachus SE, Wood GK, Weinberger DR. Amphetamineinduced c-fos mRNA expression is altered in rats with neonatal ventral hippocampal damage. Synapse. 1996;23(4):292-301.
48. Lillrank SM, Lipska BK, Kolachana BS. Attenuated extracellular dopamine levels after stress and amphetamine in the nucleus accumbens of rats with neonatal ventral hippocampal damage. J Neural Transmission. 1999;106:183-96.
49. Lipska BK, Chrapusta SJ, Egan MF, Weinberger DR. Neonatal excitotoxic ventral hippocampal damage alters dopamine response to mild repeated stress and to chronic haloperidol. Synapse. 1995;20(2):125-30.
50. Schroeder H, Grecksch G, Becker A, Bogerts B, Hoellt V. Alterations of the dopaminergic and glutamatergic neurotransmission in adult rats with postnatal ibotenic acid hippocmapal lesion. Psychopharmacology. 1999;145(1):61-6.
51. O'Donnell P, Lewis BL, Weinberger DR, Lipska B. Neonatal hippocampal damage alters electrophysiological properties of prefrontal cortical neurons in adult rats. Cerebral Cortex. 2002;12:975-82.
52. Goto Y, O'Donnell P. Delayed mesolimbic system alteration in a developmental animal model of Schizophrenia. J Neurosci. 2002;22(20):9070-7.
53. Chambers RA, Self DW. Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: An animal model of dual diagnosis schizophrenia. Neuropsychopharmacology. 2002;27(6):889-905.
54. Chambers RA, Potenza MN. Schizophrenia and pathological gambling (Letter). Am J Psychiatry. 2001;158(3):497-8.
55. Chambers RA, Jones RM, Brown S, Taylor JR. Natural reward related learning in rats with neonatal ventral hippocampal lesions and prior cocaine exposure. Psychopharmacology. 2005;179(2):470-8.
56. Robinson TE, Berridge KC. The neural basis of drug craving: An incentivesensitization theory of addiction. Brain Res Rev. 1993;18:247-91.
57. Pierce RC, Kalivas PW. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Rev. 1997;25:192-216.
58. Chambers RA, Taylor JR. Animal modeling dual daignosis schizophrenia: Sensitization to cocaine in rats with neonatal ventral hippocampal lesions. Biol Psychiatry. 2004;56(5):308-16.
59. Chambers RA, Sheehan T, Taylor JR. Locomotor sensitization to cocaine in rats with olfactory bulbectomy. Synapse. 2004;52:167-75.
60. Holmes PV, Masini CV, Primeaux SD, Garrett JL, Zellner A, Stogner KS et al. Intravenous self-administration of amphetamine in a rat model of depression. Synapse. 2002;46(4):4-10.